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Abstract
Heterotrophic bacteria associated with two specimens of the marine sponge Erylus discophorus were screened for their
capacity to produce bioactive compounds against a panel of human pathogens (Staphylococcus aureus wild type and
methicillin-resistant S. aureus (MRSA), Bacillus subtilis, Pseudomonas aeruginosa, Acinetobacter baumanii, Candida albicans
and Aspergillus fumigatus), fish pathogen (Aliivibrio fischeri) and environmentally relevant bacteria (Vibrio harveyi). The
sponges were collected in Berlengas Islands, Portugal. Of the 212 isolated heterotrophic bacteria belonging to Alpha- and
Gammaproteobacteria, Actinobacteria and Firmicutes, 31% produced antimicrobial metabolites. Bioactivity was found
against both Gram positive and Gram negative and clinically and environmentally relevant target microorganisms.
Bioactivity was found mainly against B. subtilis and some bioactivity against S. aureus MRSA, V. harveyi and A. fisheri. No
antifungal activity was detected. The three most bioactive genera were Pseudovibrio (47.0%), Vibrio (22.7%) and Bacillus
(7.6%). Other less bioactive genera were Labrenzia, Acinetobacter, Microbulbifer, Pseudomonas, Gordonia, Microbacterium,
Micrococcus and Mycobacterium, Paenibacillus and Staphylococcus. The search of polyketide I synthases (PKS-I) and
nonribosomal peptide synthetases (NRPSs) genes in 59 of the bioactive bacteria suggested the presence of PKS-I in 12
strains, NRPS in 3 strains and both genes in 3 strains. Our results show the potential of the bacterial community associated
with Erylus discophorus sponges as producers of bioactive compounds.
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Introduction
Due to their physico-chemical properties, which rarely exceed
the biological tolerance limits, the oceans provide a safe
environment for most living organisms [1]. However, the multiple
beings that live in the marine environment had to develop survival
strategies against other organisms with whom they have to
compete for space and food. Sharing a common environment
over a long evolutionary period also allowed the establishment of
well-balanced associations between many of these organisms. A
good example of these associations are the sponges that host a
significant microbiome which can reach up to 40–60% of the total
sponge biomass and densities of 108 to 1010 bacteria per gram of
sponge wet weight. These values can exceed seawater concentra-
tions by two to three orders of magnitude [2–5].
Natural bioactive compounds have been used since the
beginning of traditional medicine [6]. They are present in all
kinds of life forms and are produced by the secondary metabolism
of organisms. Secondary metabolites include terpenoids, alkaloids,
polyketides, peptides, shikimic acid derivates, sugars, steroids and a
large mixture of biogenesis metabolites [7]. Sponge symbionts are
fundamental in host defence against predators due to the
production of biologically active secondary metabolites. These
natural products can show antibacterial, antifungal, antiviral,
antiprotozoal, anthelmintic, anti-inflammatory, antitumor, immu-
nosuppressive, neurosuppressive properties and can also possess
activities for the treatment of cardiac, respiratory and gastrointes-
tinal diseases [8]. Sponges are the ‘‘gold mine’’ organisms for
natural product isolation (over 30% of the products) in the marine
environment [9]. The search for new drugs, especially antibiotics,
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is important due to the increase of bacterial resistance to existing
antibiotics.
The true origin of many of these bioactive molecules is
uncertain. The production of secondary metabolites could be
due to the cooperation between sponges and symbionts, only to
the symbionts or to the sponges [10;11]. A microbial origin got
support from the occurrence of structurally similar substances in
unrelated sponges (see Laport et al. [8]). The fact that these
substances may be produced by microbes could allow their
sustainable and unlimited production in vitro. This is hardly the
case with sponges. As the sponge bioactivity may in fact be due to
their microbiome, these organisms became the subject of many
works.
Secondary metabolites possess complex structures and involve
unusual biochemistry. Two families of enzymes, the polyketide
synthases (PKS) and the nonribosomal peptide synthetases
(NRPS), are of particular importance in the production of various
secondary metabolites many of which are important drugs [12].
Both PKSs and NRPSs can be conceptualized as enzymatic
‘‘assembly lines’’ composed of functional modules [13].
The discovery of new biosynthetic pathways encoding genes of
secondary metabolites opens the possibility of heterologous
production and the genetic manipulation of the gene cluster to
obtain new natural products [14]. Metagenomic analysis of the
prevalence and presence of PKS and NRPS genes are being
studied to improve the search of new bioactive compounds in
sponges (e.g. Schirmer et al. [15]).
Sponges belonging to the genus Erylus (Astrophorida, Geodii-
dae), are well known as producers of saponins and other
oligoglycosides [16–27]. These natural products have been
reported to exhibit a wide spectrum of biological activities which
include selective thrombin receptor antagonist activity and
functional activity in a platelet aggregation assay [19], immuno-
pressive activity [28], inhibition of neuraminidase from the
bacterium Clostridium perfringens [21] and antitumor and antifungal
properties [16;23;24]. Alcoholic extracts of Erylus deficiens Topsent,
1927 from the Mediterranean sea showed antibacterial activity
against the marine bacteria Alteromonas luteo-violacea and 8 terrestrial
bacteria (Staphylococcus epidermidis, Sarcina lutea, Bacillus subtilis,
Micrococcus luteus, Serratia marcescens, Enterobacter sp., Proteus morganii
and Proteus mirabilis) [29]. Antimicrobial activity against Bacillus
subtilis, Escherichia coli and Candida albicans was observed in the
extracts of Erylus lendenfeldi Sollas, 1888 collected in the Red Sea
[22]. In addition, multiple ecological functions have also been
attributed to these molecules. Furthermore, it was shown that the
sponge Erylus formosus Sollas, 1886 contained sufficiently high
concentrations of erylosides to protect itself against predatory
fishes, bacterial settlement, and fouling [30–31]. These natural
compounds have been isolated from different species of Erylus as
well as from different geographic locations [23–27]. Another
species, E. discophorus Schmidt, 1862, was reported to have
haloperoxidase with iodo- and bromoperoxidases activities [32].
In this study we aimed to assess the bioactive potential of
bacteria isolated from the marine sponge E. discophorus collected in
Berlengas Islands against a panel of pathogenic and environmental
microorganisms. Antimicrobial bioactivity was detected in 31% of
the 212 isolated heterotrophic bacteria from two specimens of E.
discophorus and the presence of PKS-I and NRPSs genes was
detected in several isolates showing the biotechnological potential
of these bacteria.
Materials and Methods
1. Biological material
The 212 bacteria (here designated test bacteria) under study
were isolated from two specimens of the sponge E. discophorus
(named Berg01 and Berg02) that were sampled nearby, at 15 m by
scuba diving in the Berlengas Islands a protected area of
UNESCO located off the W coast of Portugal (N39u 289 470;
W9u 329 780). The authors thank Reserva Natural das Berlengas
(Instituto da Conservac¸a˜o da Natureza e da Biodiversidade –
ICNB) for the sponges samples harvesting permission. Voucher
samples of the sponges were preserved in 90% ethanol for
taxonomic identification and deposited in the Biology Depart-
ment’s zoological collection of the University of the Azores
(DBUA.Por). Specimens were identified from the analysis of
general external and internal morphological characters, i.e. shape,
type, size and arrangement of skeletal structures (spicules)
following the Systema Porifera classification system [33].
The bacterial isolation was performed inoculating serial
dilutions (1021 to 1026) of the homogenized from the sponges in
heterotrophic media. After isolation in pure culture, bacteria were
cultivated in Marine Broth (Becton Dickinson, MB) in the dark at
26uC. Their taxonomic identification was based on the analysis of
the 16S rRNA gene by direct colony PCR or with template DNA
extracted by the boiling method. A loop full of bacterial culture
was resuspended in 200 ml of distilled deionized H2O and
subjected for 10 min to 100uC, cooled on ice and the extracted
DNA amplified with the universal primers 27f and 1492r [34] in
50 ml of PCR mixture (16PCR buffer; 1.5 mM MgCl2; 1 unit of
GoTaq Flexi DNA Polymerase; 200 mM of each deoxynucleoside
triphosphate (dNTPs); 2 mM of each primer). The PCR program
was performed in a MyCyclerTM Thermo Cycler (Bio-Rad) and
consisted in an initial denaturing step of 5 min at 95uC; 30 cycles
of 1 min at 94uC; 1 min at 52uC; and 90 s at 72uC; and a final
extension of 5 min at 72uC. PCR products were visualized after
electrophoresis in a 1.2% agarose gel in 1X TBE buffer. The
PCRs amplicons were sequenced at MACROGEN (Korea).
Sequences were assembled with Vector NTI 10.1 and classified
in the Ribosomal Database Project [35].
The isolated Erylus bacteria were screened for their capacity to
produce bioactive compounds against a panel of varied target
microorganisms. This includes human pathogens, a fish pathogen
and an environmentally relevant bacterium. In the Janus assays,
Bacillus subtilis (ATCC6633), Staphylococcus aureus MRSA, Acineto-
bacter baumannii and Candida albicans were tested while in the Duetz
assays Pseudomonas aeruginosa PAO1, Acinetobacter baumannii, Vibrio
harveyi (CECT 525), Aliivibrio fischeri (CECT 524), Bacillus subtilis
(ATCC6633), Staphylococcus aureus wild type Smith strain, Staphy-
lococcus aureus MRSA, Candida albicans, Aspergillus fumigatus
(ATCC46645) and (DakuBKU80) were used.
2. Screening assays for antibacterial and antifungal
activity
The search for bioactivity was performed with the 212 bacteria
isolated from E. discophorus. The isolates were initially fermented in
96-deep well Duetz plates [36] with 800 ml of MB media in each
well for 3 days at 28uC and 220 r.p.m. After incubation, 400 ml of
each culture were transferred to new 96-deep wells plates
containing 400 ml of a solution of Sea Salts (4%) and Glycerol
(40%) and kept at 228uC. These plates were designated as the
Master Plates (MP). The MPs were then used in a replication
procedure previously described [36] to generate fresh inocula (MB
medium, 2 days, 28uC, 220 rpm, 70% humidity). The inocula thus
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generated were employed to seed all subsequent micro-fermenta-
tions carried out in both Janus and Duetz plates.
2.1 Janus plates assays. This double-faced plated assay
optimized by Fundacio´n MEDINA [37] is based in exclusively
designed plates by Nunc with two sides, which allow culture
growth on the opposite layers in solid media. In order to maximize
the number of potential active secondary metabolites produced, 5
different media were chosen to carry out the miniaturized
fermentations: Marine Broth (2216 Difco), Medium F (0.015 g
K2HPO4; 0.2 g CaCl2; 0.75 g KCL; 23.4 g NaCl; 7 g MgSO4;
1 g Mannitol; 1 g Yeast extract; 1 g Peptone; 16 g Agar; 1 ml
Hutner’s basal salts [38] and 999 ml ddH2O), R2A (218263 -
Difco) and saline (supplemented with 3% of SeaSalts of Sigma)
R2A and Starch Agar (Difco).
On the top layer of the Janus plates the test bacteria were
inoculated employing a replication procedure previously described
[36] and incubated for 3 days at 28uC and 70% of humidity.
Subsequently, the inoculated media with the target microorgan-
isms were added on the opposite side thus forming the assay layer.
The double-faced Janus plates were incubated at 37uC for 20–
24 h. A search of inhibition zones indicative of antibacterial or
antifungal activity was then carried out [37]. This in vitro screening
assay was performed against a panel of Gram positive bacteria
(Bacillus subtilis (ATCC6633) and Staphylococcus aureus MRSA),
Gram negative bacteria (Acinetobacter baumannii) and the yeast
Candida albicans. All target organisms were pre-inoculated and
grown at 28uC, 220 r.p.m. for 12 h and 70% of humidity. Pre-
inoculum and inoculum medium used to grow A. baumannii and B.
subtilis was Luria Broth (LB) (Miller’s, Invitrogen). For C. albicans
the pre-inoculum medium was Sabouraud Dextrose Broth (SDB)
and the inoculum medium was YNBD [37]. The pre-inoculum
and inoculum medium prepared for the overnight growth of S.
aureus MRSA was Brain Heart Infusion (BHI). Inocula absorbance
for all target microorganisms was adjusted to a final 600 nm
optical density (OD) of 0.4 before being placed in the Janus plates.
Non-inoculated medium was used as negative control.
Tests of growth interference of the target microorganisms with
saline media were performed in advance to rule out possible
interferences.
2.2 Microfermentations in 96-deep well plates. MPs were
used to carry out microfermentations in 96-deep well plates (here
designated by Duetz system assay) following the approach
described by Duetz et al. [36]. For this assay, besides the 5 media
already specified for the Janus plates, half saline concentration of
the media were also tested. The inoculated Duetz plates were
incubated (1 mL) for 5 days at 28uC, 220 r.p.m. and 70% of
humidity. Bacterial broth were then subjected to an organic
extraction with 800 ml acetone and 40 ml DMSO per well. The
plates were incubated for 1 h at 220 r.p.m. and then transferred to
a vacuum centrifuge (GeneVac HT-24) in order to reduce the final
volume to 400 ml (2 Whole Broth Equivalent). The supernatants of
the extracts solutions were transferred to 96-deep well plates. The
organic extracts were then assayed against the Gram-negative
Pseudomonas aeruginosa PAO1, Acinetobacter baumannii, Vibrio harveyi
(CECT 525) and Aliivibrio fischeri (CECT 524); and the Gram-
positive Bacillus subtilis (ATCC6633), Staphylococcus aureus wild type
Smith strain and Staphylococcus aureus MRSA. Antifungal assays
were also prepared against the yeast Candida albicans and Aspergillus
fumigatus (ATCC46645) and (DakuBKU80). Unless specified nega-
tive controls were always uncultivated culture medium.
For the screening assays against Acinetobacter baumannii, S. aureus
(Smith), Pseudomas aeruginosa PAO1 and Candida albicans, overnight
cultures grown in liquid Luria Broth (Miller’s media) at 37uC and
220 r.p.m. were measured at an absorbance of 612 nm for A.
baumannii and S. aureus (Smith) and 600 nm for P. aeruginosa. The
inocula in LB media were adjusted to an OD of 56105 for A.
baumannii and to a cell concentration of 2.56105 CFU/ml for S.
aureus (Smith) and 56105 CFU/ml for P. aeruginosa. A suspension
of C. albicans in medium RPMI (40 ml 1 M HEPES; 36 ml 50%
glucose; 6.7 g Yeast Nitrogen Broth without amino acids; RPMI a
bottle; adjust pH to 7.1 and 0.22 mm sterilized) was adjusted to
0.250 at 660 nm. This suspension was then diluted 1/10.
For the liquid screens, Nunc plates (LTC-330) were filled as
follows: 10 ml of each extract plus 90 ml of inoculum in 80 wells;
10 ml of a series of antibiotic concentrations in the range of the
minimum inhibitory concentration plus 90 ml of inoculum (positive
and negative controls) in 8 wells; 100 ml (90 ml of LB media +10 ml
DMSO 20%) as blank control in 4 wells; and 100 ml of the
inoculum for the assessment of the total microorganism growth.
The antibiotics used against A. baumannii were, as positive controls,
0.3125, 0.625, 12.5 and 25 mg.mL21 rifampicin and, as negative
controls, 7.8125, 15.625, 31.25 and 62.5 mg.mL21 amphotericin
B. In the case of P. aeruginosa the positive controls were 1.9625,
3.925, 7.85 and 15.7 mg.mL21 ciprofloxacin and the negative
controls were 7.8125, 15.625, 31.25 and 62.5 mg.mL21 ampho-
tericin B. In the assays performed with S. aureus (Smith) the positive
controls used were serially diluted between 0.561027 to
5 mg.mL21 penicillin G and with C. albicans the antibiotics used
were as positive controls 7.8125, 15.625, 31.25 and 62.5 mg.mL21
amphotericin B and as negative controls 0.039, 0.078, 0.156 and
0.312 mg.mL21 penicillin G.
The plates were incubated at 37uC for 20 h under humid
conditions. The absorbances were measured at 612 nm in a Tecan
ULTRAEVOLUCION before and after incubation. To confirm
the results, 30 ml of a 0.02% resazurin stock solution was added to
each well (100 ml) and incubated for 2 h. Changes in colour from
blue (growth inhibition corresponding to detection of bioactivity)
to pink (no growth inhibition corresponding to no detection of
bioactivity) and fluorescence readings radiated from the resazurin
were measured in a Perkin Elmer VICTOR2 multi-function
fluorometer. All ODs and fluorescence measurements were
analysed using the Genedata Screener software.
For the screening assays against Aspergillus fumigatus ATCC46645
and DakuBKU80, cultures of both A. fumigatus were prepared in
medium RPMI with 0.002% resazurin from a stock spore
suspension in Tween saline buffer to a final concentration of
2.56104 conidia/ml as described by Monteiro et al. [39]. The
assays were carried out as previously described, using as positive
controls 0.5, 1.0, 2.0 and 4.0 mg.mL21 amphotericin B. The plates
were incubated for 30 h at 37uC and, then, the fluorescence was
recorded in a Perkin Elmer VICTOR22TM Multi-function
fluorometer.
For the screening assays against Staphylococcus aureus MRSA, an
overnight culture of S. aureus MRSA in 10 ml of liquid Brain Heart
Infusion (BHI) medium was incubated at 37uC and 220 r.p.m.
The OD of the culture measured at 660 nm was adjusted to 0.2
and used to inoculate BHI agar medium (3 ml of the adjusted
inoculum per 100 ml of medium) which was then distributed
(30 ml) in OmnyTray plates. Disposable 96 pin trays were used to
generate 96 wells in each of the BHI agar plates in which,
subsequently, 10 ml of each extract in each well were dispensed.
Alternatively extracts were distributed in BHI agar plates without
wells. Ten ml of 0.5 mg.mL21 kanamycin was used as positive
control. Plates were then incubated at 37uC for 20 h and zones of
inhibition (ZOI) were measured. Any extract producing a visibly
discernible ZOI, regardless of zone quality, was considered to be
positive.
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For the screening assays against Bacillus subtilis (ATCC 6633), a
culture of B. subtilis was prepared using 1 ml of spore suspension/
1 L medium (23 g/L of Nutrient Agar and 2 g/L of yeast extract)
that had been previously sonicated for 3 min. The assay was
performed in a similar way to the one used against S. aureus MRSA
and the positive control was 150 mg/ml tunicamycin.
Screening assays against Vibrio harveyi CECT 525 and Aliivibrio
fischeri CECT 524 were carried out in a cell density optimized agar
assay. Ten ml of Luminous Medium [40] were inoculated with a
loop of the pure V. harveyi and A. fischeri, incubated at 25uC,
220 r.p.m. for 12 h and the optical density adjusted to 0.3 for V.
harveyi and 0.4 for A. fischeri at 600 nm and, subsequently, both
diluted by 1/10. The assay was performed in a similar way to the
one used against S. aureus MRSA and the positive control consisted
on 0.256 mg/ml chloramphenicol. The cultures were incubated at
25uC for 24 h. Inhibition was detected with the presence of non-
phosphorescent halos in a dark-room.
3. Search of PKS and NRPS genes
The molecular analysis of the genes PKS-I and NRPS involved
in the production of secondary metabolites was investigated in the
59 of the bioactive bacteria. Genomic DNA was extracted with an
E.Z.N.A. bacterial KIT from OMEGA. Specific degenerated
primers MDPQQRf and HGTGTr [41] and DKf and MTr [42]
were used for PCR amplification of PKS-I and NRPS genes,
respectively. A total of 25 ml of PCR mixture (16PCR buffer with
1.7 mM MgCl2; 0.8 unit of Go Taq DNA Polymerase; 0.2 mM of
each dNTPs; 0.1 mM of each primer and 5 ml DNA template) was
used. The PCR program for the genes PKS-I and NRPS was the
same and consisted of an initial denaturing step of 5 min at 95uC;
11 cycles of 1 min at 95uC; 30 s at 60uC and 1 min at 72uC, with
the annealing temperature reduced by 2uC per cycle, followed by
30 cycles of 95uC for 1 min, 40uC for 30 s and 72uC for 1 min
with a final extension of 10 min at 72uC. The PCR programs were
performed in an MyCyclerTM Thermo Cycler (Bio-Rad) and the
PCR products were visualized in VWR GenoPlex after electro-
phoresis in a 1.2% agarose gel in 1X TAE buffer.
Results and Discussion
The oceans, an almost endless source of microbial diversity, are
the habitat of organisms such as sponges that harbour a large
microbial diversity with important biosynthetic potential due to
their secondary metabolites profiles [43]. The analysis of sponge
symbionts in pure cultures is an advantage for the performance of
bioactive screening assays [44] and is the most direct method for
the large-scale production of bioactive compounds [45]. The two
specimens of Erylus discophorus collected in Berlengas (Berg01 and
Berg02) allowed the isolation of a large number of heterotrophic
bacteria (212 isolates) of which 31% (66 isolates) showed
bioactivity. Of the screened bacteria for bioactivity and based on
the 16S rDNA gene analysis, 57% (n= 120) were Alphaproteobacteria,
21% (n= 45) Gammaproteobacteria, 16% (n= 34) Actinobacteria and
6% (n= 13) Firmicutes.
Bioactivity was observed against one or more of the target
microorganisms tested. The majority was active against Bacillus
subtilis (87.9%) and at a lower percentage against Staphylococcus
aureus MRSA (10.6%), Aliivibrio fischeri (9.1%) and Vibrio harveyi
(6.1%). Bacteria with bioactivity against both B. subtilis and S.
aureus MRSA represented 9.1% and against both A. fischeri and V.
harveyi accounted for 4.6%. No bioactivity was observed against P.
aeroginosa, A. baumannii, S. aureus wild type, C. albicans and A.
fumigatus.
The taxonomic affiliation of all bioactive isolates is provided in
Table 1.
Table 2 correlates the taxonomic position of the isolates genera
and their relative bioactivity percentage. It also specifies the
number and relative percentage of bioactive isolates obtained with
the Janus and Duetz systems. Thirty two isolates of Alphaproteo-
bacteria (48.5%) belonging to the genera Pseudobrivio and Labrenzia
were bioactive against B. subtilis, S. aureus MRSA and A. fischeri.
Eighteen isolates of Gammaproteobacteria (27.3%) belonging to the
genera Vibrio, Acinetobacter, Microbulbifer and Pseudomonas were active
against B. subtilis, V. harveyi and A. fischeri. Eight isolates of
Actinobacteria (12.1%) belonging to the genera Gordonia, Microbacte-
rium, Micrococcus and Mycobacterium were active against B. subtilis
and S. aureus MRSA. Eight isolates of Firmicutes (12.1%) belonging
to the genera Bacillus, Paenibacillus, Sporosarcina and Staphylococcus
were active against B. subtilis, V. harveyi and A. fischeri. Pseudovibrio
(47.0%), Vibrio (22.7%) and Bacillus (7.6%) are the three most
bioactive genera of all the bioactive isolates. No activity was
observed in isolates affiliated to Ruegeria, Rhodobacter, Erythrobacter,
Martelella, Nautella, Photobacterium, Thalassomonas, Rhodococcus and
Dietzia.
The group with the higher number of isolates demonstrating
bioactivity was the Alphaproteobacteria followed by the Gammaproteo-
bacteria, Actinobacteria and Firmicutes. However, if the analysis is
made based on the number of bioactive isolates relative to the total
number of bacteria in each group, Firmicutes are the most bioactive
(61.5%) followed by Gammaproteobacteria (40%), Alphaproteobacteria
(26.7%) and Actinobacteria (23.5%). Bioactivity results obtained with
marine bacteria and sponge associated bacteria are somehow
different. Regarding marine bacteria in general, most of the new
marine bacterial compounds from 1997 to 2008 were originated
from Actinobacteria (40%), Cyanobacteria (33%), Proteobacteria (12%)
and Firmicutes and Bacteroidetes (5% each) [46]. The distribution of
bioactive compounds produced by sponge associated bacteria is
Actinobacteria (46.66%), Proteobacteria (23.33%), Firmicutes (11.66%),
Cyanobacteria (8.33%), Verrucomicrobia (5%) and others (5%) [47].
The high number of bioactive Actinobacteria may be biased due to
their extensive study in the production of antibiotic compounds
since 50% of known microbial antibiotics are derived from these
bacteria [48].
Several of the obtained bioactive genera are well known
producers of metabolites with antimicrobial properties but others
are less known. Furthermore, many of the examples referred to
below are from sponge associated bacterial isolates.
A suite of antimicrobial compounds with spectra of different
antimicrobial activity was observed in Pseudovibrio [11;49–52]. A
sponge associated Alphaproteobacterium related to Pseudovibrio deni-
trificans, displayed a weak and unstable antimicrobial activity,
which was easily lost during cultivation [53]. However, this
bioactive bacterium was present in the sponges in high numbers.
High antimicrobial activity was also observed in isolates from soft
corals affiliated to the alphaproteobacterium Labrenzia [51].
Marine vibrios have been reported as a rich source of novel
biologically active metabolites [10;51;54–57]. Bioactivity produced
by Vibrio sp. and sponge extracts was observed against Bacillus [58].
A total of 93 secondary metabolites were isolated from Vibrionaceae
[59]. These are surface-associated bacteria known to produce a
broad range of antibacterial compounds which may have a
relevant ecological role favouring their abundance in microbial
communities [59].
Bioactive metabolites produced by marine Pseudomonas species
have been reported [10;54;55;60–62]. Marine Pseudomonas spp. as
potential source for medically relevant bioactive substances were
revised by Isnansetyo and Kamei [63].
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Table 1. Taxonomic affiliation of the bioactive bacteria isolated from E. discophorus.
Isolate Closest strain; Accession no. Similarity Genera Phylum/Class
Berg02_22.2 Gordonia sp. DEOB200; AY927227 100,0% Gordonia Actinobacteria
Berg02_29 Gordonia sp. CNJ786 PL04; DQ448772 98.6% Gordonia Actinobacteria
Berg02_78 Gordonia terrae; 3269aBRRJ; FJ200386 99.6% Gordonia Actinobacteria
Berg02_79 Microbacterium sp. M63-2; EF061897 98.8% Microbacterium Actinobacteria
Berg02_79a Microbacterium sp. M63-2; EF061897 99.7% Microbacterium Actinobacteria
Berg02_11 Micrococcus sp. LJY5; EU379020 99.7% Micrococcus Actinobacteria
Berg02_26 Micrococcus luteus; KCL-1; DQ538135 98.7% Micrococcus Actinobacteria
Berg01_46 Mycobacterium sp. JL838; DQ985057 96.9% Mycobacterium Actinobacteria
Berg02_114.2 alpha proteobacterium CRA 40S; AY562568 96.4% Labrenzia Alphaproteobacteria
Berg01_7 Pseudovibrio ascidiaceicola 100.0% Pseudovibrio Alphaproteobacteria
Berg01_9 Pseudovibrio ascidiaceicola (T); F423( = NBRC
100514); AB175663
99.8% Pseudovibrio Alphaproteobacteria
Berg01_16 sponge bacterium Isolate3; AY948383 98.3% Pseudovibrio Alphaproteobacteria
Berg01_33 alpha proteobacterium CRA 3GB; AY562562 96.2% Pseudovibrio Alphaproteobacteria
Berg01_50 alpha proteobacterium CRA 3GB; AY562562 99.6% Pseudovibrio Alphaproteobacteria
Berg01_68 Pseudovibrio sp. B411; FN295808 98.1% Pseudovibrio Alphaproteobacteria
Berg01_77 Pseudovibrio sp. PV4; EU768841 98.9% Pseudovibrio Alphaproteobacteria
Berg02_8.1 alpha proteobacterium CRA 3GB; AY562562 98.6% Pseudovibrio Alphaproteobacteria
Berg02_8.3 sponge bacterium Isolate1; AY948382 93.7% Pseudovibrio Alphaproteobacteria
Berg02_9.1 alpha proteobacterium CRA 3GB; AY562562 99.4% Pseudovibrio Alphaproteobacteria
Berg02_10.1 Pseudovibrio sp. PV4; EU768841 99.2% Pseudovibrio Alphaproteobacteria
Berg02_10c alpha proteobacterium CRA 3GB; AY562562 99.3% Pseudovibrio Alphaproteobacteria
Berg02_13.1 Pseudovibrio sp. PV4; EU768841 99.2% Pseudovibrio Alphaproteobacteria
Berg02_17 Pseudovibrio sp. PV4; EU768841 98.7% Pseudovibrio Alphaproteobacteria
Berg02_18 sponge bacterium Isolate1; AY948382 96.0% Pseudovibrio Alphaproteobacteria
Berg02_36 alpha proteobacterium CRA 3GB; AY562562 97.1% Pseudovibrio Alphaproteobacteria
Berg02_39.1 sponge bacterium Isolate3; AY948383 98.3% Pseudovibrio Alphaproteobacteria
Berg02_39.3 sponge bacterium Isolate1; AY948382 99.5% Pseudovibrio Alphaproteobacteria
Berg02_40 sponge bacterium Isolate1; AY948382 98.4% Pseudovibrio Alphaproteobacteria
Berg02_41 alpha proteobacterium CRA 3GB; AY562562 98.8% Pseudovibrio Alphaproteobacteria
Berg02_50 alpha proteobacterium CRA 3GB; AY562562 96.4% Pseudovibrio Alphaproteobacteria
Berg02_51 alpha proteobacterium CRA 57G; AY562561 96.6% Pseudovibrio Alphaproteobacteria
Berg02_54.1 Pseudovibrio sp. PV4; EU768841 99.3% Pseudovibrio Alphaproteobacteria
Berg02_56.2 alpha proteobacterium CRA 3GB; AY562562 98.6% Pseudovibrio Alphaproteobacteria
Berg02_57 sponge bacterium Isolate3; AY948383 98.3% Pseudovibrio Alphaproteobacteria
Berg02_58 Pseudovibrio sp. PV4; EU768841 98.8% Pseudovibrio Alphaproteobacteria
Berg02_61 Pseudovibrio ascidiaceicola (T); F423( = NBRC
100514); AB175663
97.4% Pseudovibrio Alphaproteobacteria
Berg02_63 sponge bacterium Isolate1; AY948382 99.4% Pseudovibrio Alphaproteobacteria
Berg02_65 Pseudovibrio ascidiaceicola (T); F423( = NBRC
100514); AB175663
100,0% Pseudovibrio Alphaproteobacteria
Berg02_141 sponge bacterium Isolate1; AY948382 99.6% Pseudovibrio Alphaproteobacteria
Berg02_188 sponge bacterium Isolate3; AY948383 98.0% Pseudovibrio Alphaproteobacteria
Berg01_47 Bacillus circulans 99.0% Bacillus Firmicutes
Berg01_48 Bacillus circulans (T); AY043084 97.9% Bacillus Firmicutes
Berg01_114 Bacillus sp. enrichment culture clone SYW22;
FJ601652
99.9% Bacillus Firmicutes
Berg02_107 Bacillus megaterium; MO31; AY553118 100.0% Bacillus Firmicutes
Berg02_161a Bacillus sp. RS654(2010); GU968484 99.6% Bacillus Firmicutes
Berg01_119 Paenibacillus sp. 1 GUW; EU496552 99.6% Paenibacillus Firmicutes
Berg02_117 Sporosarcina luteola 99.9% Sporosarcina Firmicutes
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The production of antibacterial compounds by a halotolerant
Acinetobacter sp. from saltpans of Ribandar, Goa was observed [64].
Acinetobacter from the ascidian Stomozoa murrayi [65] also produced
bioactive compounds. Microbulbifer produce anticancer antibiotics
(pelagiomicins) [66] and a broad variety of natural parabens [67].
Further evidence of production of antimicrobial activity by
Microbulbifer was obtained by Penesyan et al. [68].
Bacillus spp. from terrestrial origin are well known sources of
antimicrobial compounds [69]. Similarly antibiotics/bioactive
compounds from marine Bacillus spp. have also been reported
[10;53;55–57;70;71]. Genome sequencing studies of the genus
Bacillus have revealed its potential as a source of antibiotic-like
compounds [72].
Antimicrobial activity of the Gram negative strains Paenibacillus
sp., P. elgii, P. polymyxa and P. koreensis has been observed [70;73–
75]. Anand et al. [55] observed bioactivity in Staphylococcus bacteria
isolated from four species of sponges.
Micrococcus strains possessing antimicrobial activity were de-
scribed by Bultel-Ponce´ et al. [61], Hentschel et al. [76] and Lo
Giudice et al. [77]. Antitumor and antimicrobial bioactivity was
observed by Microbacterium species [57;78;79]. In a recent review
the actinomycete genus Gordonia was described as being capable of
degrading xenobiotics, environmental pollutants, or otherwise
slowly biodegradable natural polymers as well as to transform or
synthesize possibly useful compounds [80]. However, to our
knowledge, no antimicrobial activity has been associated with this
genus, nor with the Mycobacterium genus which is well known for its
infectivity.
The most efficient liquid medium for the production of
bioactive compounds against B. subtilis, S. aureus MRSA, V. harveyi
and A. fischeri was MB. In saline R2A bioactivity was observed
against both S. aureus MRSA and V. harveyi, and in saline Starch
and MF against A. fischeri. In solid media assays, higher numbers of
inhibitions were observed in saline Starch followed by MF and
saline R2A. No inhibitions were found in MA medium when used
as culture medium in the Janus system. The non-saline R2A
medium was the only one where no bioactive compounds were
produced in both systems.
The screening of the 212 bacteria was performed using two
different plate systems. The Duetz system is a miniaturized
fermentation system that allows carrying out a high number of
microfermentations with a lot less effort than the effort required to
carry out the fermentations in tubes/flasks. Bacteria are fermented
in liquid media, crude extracts are obtained and assayed for
bioactivity against target organisms. However, in the double-faced
diffusion assay Janus system, after the initial growth of the sponge
isolates, the medium, containing diffused secondary metabolites is
put in contact with the target organism to assess inhibitory
responses. The Janus system allowed the assessment of a higher
number of bioactive positive hits (84%) when compared to the
Duetz system (16%). However, the Duetz results are more reliable
than the ones obtained with the Janus plates due to the overlap of
inhibition halos in the latter. Moreover, due to bacterial swarming
and gliding, results in the Janus system were obtained after 3 days
of incubation, whereas longer incubation times were employed in
the liquid microfermentations. Bacterial swarming and gliding also
interfered with the visualization of results in other antimicrobial
studies [37;53].
It is well known that microbial secondary metabolite production
is highly-dependent on the fermentation conditions [81]. Growth
media and growth conditions are variables that are known to have
effects on the production of bioactive compounds and can be
different depending on the strains [82]. As the production of
secondary metabolites is mainly observed in late exponential/
stationary phases, bacteria should produce more bioactive
compounds after 5 days than 3. This hypothesis could be true
for some bacteria and may explain some of the different bioactivity
percentages obtained with the two methods. Furthermore, being
Table 1. Cont.
Isolate Closest strain; Accession no. Similarity Genera Phylum/Class
Berg02_67 uncultured bacterium; nbu377a05c1; GQ035792 99.0% Staphylococcus Firmicutes
Berg02_21 Acinetobacter sp. PmeaMuc16; EU249988 98.0% Acinetobacter Gammaproteobacteria
Berg02_116 Microbulbifer cystodytense; C1; AJ620879 97.4% Microbulbifer Gammaproteobacteria
Berg02_77 Pseudomonas sp. CJ11064; AF500211 99.8% Pseudomonas Gammaproteobacteria
Berg02_5 Vibrio sp. Mel 35; AJ582806 100.0% Vibrio Gammaproteobacteria
Berg02_6 Vibrio sp. Mel 35; AJ582806 100.0% Vibrio Gammaproteobacteria
Berg02_16 Vibrio sp. Mel 35; AJ582806 100.0% Vibrio Gammaproteobacteria
Berg02_19 Vibrio sp. BBsea_03; JF792677 100.0% Vibrio Gammaproteobacteria
Berg02_22 Vibrio alginolyticus; UDC324; GQ245913 98.5% Vibrio Gammaproteobacteria
Berg02_23 Vibrio splendidus; DCM1; AY227706 99.9% Vibrio Gammaproteobacteria
Berg02_24 Vibrio sp. Mel 35; AJ582806 97.9% Vibrio Gammaproteobacteria
Berg02_28 Vibrio alginolyticus; UDC324; GQ245913 98.8% Vibrio Gammaproteobacteria
Berg02_45 Vibrio splendidus; 01/114; AJ874362 99.8% Vibrio Gammaproteobacteria
Berg02_47 Vibrio sp. BBsea_03; JF792677 99.9% Vibrio Gammaproteobacteria
Berg02_53 Vibrio sp. BBsea_05; JF792679 99.5% Vibrio Gammaproteobacteria
Berg02_64.2 Vibrio sp. Mel 35; AJ582806 100.0% Vibrio Gammaproteobacteria
Berg02_80 Vibrio sp. 5C3; EU517625 99.6% Vibrio Gammaproteobacteria
Berg02_104a Vibrio crassostreae; LGP 8; AJ582809 100.0% Vibrio Gammaproteobacteria
Berg02_105a Vibrio sp. Mel 35; AJ582806 99.4% Vibrio Gammaproteobacteria
doi:10.1371/journal.pone.0078992.t001
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Janus plates assay a microbial culturing system, the production of
secondary metabolites is possibly continued along the entire assay
at least for some bacteria able to grow at 37uC (incubation
temperature of the target microorganisms). Thus some bacteria
might be able to produce bioactive compounds in a continuous
way for longer while in direct contact with target microorganisms
[37]. It is important to notice that assays performed with Duetz
systems are cultivated in individual wells, oppositely to the Janus
assays where the cultivation of the 95 bacteria was performed in
the surface of agar without barriers. Therefore, there might be
competition for nutrients, growth inhibition due to metabolites
produced by the neighbours or even the synergic or antagonistic
interaction of two or more bacteria in the production of secondary
bioactive metabolites. Thus, this system is not as ‘‘clean’’ as the
individual fermentations in Duetz. These aspects can also have
some repercussion in the number of hits that were obtained with
the two approaches
The search for PKS-I and NRPS genes in 59 of the bioactive
bacteria revealed that 30.5% (n= 18) of the bacteria amplified one
or two of the genes for secondary metabolites. The presence of
PKS-I was observed in 12 strains, NRPS in 3 strains and both
PKS-I and NRPS in 3 strains (Table 3). The non-amplification of
any of these genes in bioactive bacteria (69.5%) suggests that these
strains should amplify with other specific primers for the PKS-I
and NRPS genes or use other metabolic pathway for the
production of secondary metabolites like PKS-II gene [83].
The majority of the bioactive bacteria that amplified PKS-I and
NRPS genes belongs to the genus Pseudovibrio (n = 10). These genes
were already reported in Pseudovibrio strains isolated from a
Irciniidae sponge [84;85]
Although a high number of the bioactive bacteria belongs to the
genus Vibrio, only 3 bacteria amplified the PKS-I gene and none
the NRPS gene. A recent review on the family Vibrionaceae suggests
that only NRPS or hybrid PKS-NRPS genes were amplified [59].
Furthermore, the genus Gordonia (n = 2), Bacillus (n = 2) and
Pseudomonas (n = 1) amplified the genes NRPS and PKS in lower
numbers.
PKS and NRPS genes have been extensively studied in
Actinobacteria of the genera Streptomyces, Mycobacterium, Corynebacteri-
um, Micromonospora [86–91] and Gordonia [92].
A wide range of bacterial groups were tested for the presence of
the genes PKS and NRPS and they were found among other
genera in Pseudomonas, Vibrio and Bacillus [93].
These results confirm the production of secondary active
metabolites by some Erylus strains that are, thus, the most
promising ones for future work.
The complex bacterial communities in marine sponges play a
considerable ecological role in several aspects of the biology of
these organisms, namely by the production of secondary
Table 3. Presence of PKS-I and NRPS genes in the bioactive E. discophorus bacteria.
Isolate Closest strain; accession no. Genera Gene present
Berg02_22.2 Gordonia sp. DEOB200; AY927227 Gordonia PKS-I
Berg02_78 Gordonia terrae; 3269aBRRJ; FJ200386 Gordonia NRPS/PKS-I
Berg01_7 Pseudovibrio ascidiaceicola Pseudovibrio PKS-I
Berg01_9 Pseudovibrio ascidiaceicola (T); F423( = NBRC 100514); AB175663 Pseudovibrio PKS-I
Berg01_16 sponge bacterium Isolate3; AY948383 Pseudovibrio PKS-I
Berg01_33 alpha proteobacterium CRA 3GB; AY562562 Pseudovibrio PKS-I
Berg02_8.1 alpha proteobacterium CRA 3GB; AY562562 Pseudovibrio PKS-I
Berg02_8.3 sponge bacterium Isolate1; AY948382 Pseudovibrio N/D
Berg02_9.1 alpha proteobacterium CRA 3GB; AY562562 Pseudovibrio N/D
Berg02_36 alpha proteobacterium CRA 3GB; AY562562 Pseudovibrio N/D
Berg02_39.1 sponge bacterium Isolate3; AY948383 Pseudovibrio NRPS/PKS-I
Berg02_39.3 sponge bacterium Isolate1; AY948382 Pseudovibrio NRPS/PKS-I
Berg02_40 sponge bacterium Isolate1; AY948382 Pseudovibrio PKS-I
Berg02_61 Pseudovibrio ascidiaceicola (T); F423( = NBRC 100514); AB175663 Pseudovibrio PKS-I
Berg02_63 sponge bacterium Isolate1; AY948382 Pseudovibrio N/D
Berg02_65 Pseudovibrio ascidiaceicola (T); F423( = NBRC 100514); AB175663 Pseudovibrio N/D
Berg02_141 sponge bacterium Isolate1; AY948382 Pseudovibrio PKS-I
Berg02_188 sponge bacterium Isolate3; AY948383 Pseudovibrio N/D
Berg01_114 Bacillus sp. enrichment culture clone SYW22; FJ601652 Bacillus NRPS
Berg02_161a Bacillus sp. RS654(2010); GU968484 Bacillus NRPS
Berg02_117 Sporosarcina luteola Sporosarcina N/D
Berg02_77 Pseudomonas sp. CJ11064; AF500211 Pseudomonas NRPS
Berg02_64.2 Vibrio sp. Mel 35; AJ582806 Vibrio PKS-I
Berg02_104a Vibrio crassostreae; LGP 8; AJ582809 Vibrio PKS-I
Berg02_105a Vibrio sp. Mel 35; AJ582806 Vibrio PKS-I
Bacteria that did not amplify for any of the genes are not shown.
N/D – not determined.
doi:10.1371/journal.pone.0078992.t003
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metabolites fundamental for sponge protection against other
organisms. These communities have thus a great biotechnological
importance in the search for new and more effective pharmaceu-
tical drugs needed for the treatment of severe human diseases such
as cancer, microbial infections and inflammatory processes. Our
results evidenced the bioactive potential of the heterotrophic
bacterial community of the sponge Erylus discophorus and open the
way for further studies.
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